Andersen, Kathleen M.Kelly, AyanoLyddiatt, AnneBingham, Clifton O.Bykerk, Vivian PatriciaBatterman, AdenaWestreich, JoanJones, Michelle K.Cross, Marita J.Brooks, PeterMarch, Lyn2022-06-170315-162Xhttp://hdl.handle.net/1885/267358Objective. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.RC is supported by a core grant from the Oak Foundation (OCAY-13-309). COB/MKJ and this work supported in part by US National Institutes of Health NIH-AR072574 Core B, and the Camille Julia Morgan Arthritis Research and Education Fund.application/pdfen-AU© 2019 The authorsOMERACTDRUG TOXICITYRISKPATIENT SATISFACTIONCLINICAL TRIALSDISEASE-MODIFYING ANTIRHEUMATIC DRUGS201910.3899/jrheum.1811852021-02-21